It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Lung mast cells are important in host defense, and excessive proliferation or activation of these cells can cause chronic inflammatory disorders like asthma. Two parallel pathways induced by KIT–stem cell factor (SCF) and FcεRI–immunoglobulin E interactions are critical for the proliferation and activation of mast cells, respectively. Here, we report that mast cell-expressed membrane protein1 (MCEMP1), a lung-specific surface protein, functions as an adaptor for KIT, which promotes SCF-mediated mast cell proliferation. MCEMP1 elicits intracellular signaling through its cytoplasmic immunoreceptor tyrosine-based activation motif and forms a complex with KIT to enhance its autophosphorylation and activation. Consequently, MCEMP1 deficiency impairs SCF-induced peritoneal mast cell proliferation in vitro and lung mast cell expansion in vivo. Mcemp1-deficient mice exhibit reduced airway inflammation and lung impairment in chronic asthma mouse models. This study shows lung-specific MCEMP1 as an adaptor for KIT to facilitate SCF-mediated mast cell proliferation.
Mast cells are activated and proliferate during allergic reactions which can involve mast cell specific proteins. Here the authors show that mast cell-expressed membrane protein1 (MCEMP1) is an adaptor for KIT to promote SCF mediated mast cell proliferation and lack of MCEMP1 reduces inflammation in mouse asthma models.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 Lerner Research Institute, Cleveland Clinic, Department of Cancer Biology, Infection Biology Program, and Global Center for Pathogen and Human Health Research, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725); University of Southern California, Department of Molecular Microbiology and Immunology, Keck School of Medicine, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853)
2 University of Southern California, Department of Molecular Microbiology and Immunology, Keck School of Medicine, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853); Kyungpook National University, School of Life Sciences, BK21 FOUR KNU Creative BioResearch Group, Daegu, South Korea (GRID:grid.258803.4) (ISNI:0000 0001 0661 1556)
3 Lerner Research Institute, Cleveland Clinic, Department of Cancer Biology, Infection Biology Program, and Global Center for Pathogen and Human Health Research, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725)
4 Lerner Research Institute, Cleveland Clinic, Department of Inflammation and Immunity, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725)
5 Lerner Research Institute, Cleveland Clinic, Department of Cancer Biology, Infection Biology Program, and Global Center for Pathogen and Human Health Research, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725); University of Southern California, Department of Molecular Microbiology and Immunology, Keck School of Medicine, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853); Cleveland Clinic, Florida Research and Innovation Center, Port Saint Lucie, USA (GRID:grid.418628.1) (ISNI:0000 0004 0481 997X)
6 University of Southern California, Department of Molecular Microbiology and Immunology, Keck School of Medicine, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853); Amgen Inc., One Amgen Center Drive, Biosafety Development Group, Cellular Sciences Department, Thousand Oaks, USA (GRID:grid.417886.4) (ISNI:0000 0001 0657 5612)
7 University of Southern California, Department of Molecular Microbiology and Immunology, Keck School of Medicine, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853)